Effect of Shexiang Baoxin pill combined with dual antibody therapy on myocardial perfusion and cardiac function outcome after PCI in acute myocardial infarction patients
Objective To explore the therapeutic effect of Shexiang Baoxin pill combined with dual antibody therapy on myocardial perfusion after percutaneous coronary intervention(PCI)in acute myocardial infarction patients and its effect on cardiac function out-come.Methods A total of 180 patients with acute myocardial infarction undergoing PCI in the Department of Cardiology of Hebi Peo-ple's Hospital from January 2019 to January 2020 were randomly assigned into dual antibody group and combination group,with 90 cases in each group.Aspirin and clopidogrel were taken orally in the dual antibody group,and Shexiang Baoxin pill was given addition-ally to the combination group on the basis of the dual antibody therapy.The clinical efficacies of the two groups were observed,and the differences in postoperative myocardial perfusion indexes were compared by cardiac imaging examination.The outcome of cardiac func-tion after treatment was evaluated with reference to Killip grading,and the changes of growth differentiation factor-15(GDF-15),hyper-sensitive C reactive protein(hs-CRP)and cardiac troponin(CTNI)were measured before and after treatment,and the incidence of major cardiovascular events during hospitalization was counted.Results After treatment,the total effective rate of the combination group(84.44%)was higher than that of the dual antibody group(66.67%)(P<0.05).After treatment,the proportion of patients with grade 3 blood flow in the thrombolysis in myocardial infarction(TIMI)test in the combination group(91.11%)was higher than that in the dual antibody group(78.89%).Compared with the corrected TIMI frame count(CTFC)before treatment,CTFCs after treatment in both the combination group and the dual antibody group decreased[(15.39±2.21)frames vs.(29.65±1.36)frames,(20.65±2.75)frames vs.(29.25±1.47)frames;P<0.05]and that in the combination group was even lower(P<0.05).The Killip classification for heart function in the two groups of patients after treatment was better than that before treatment(P<0.05),but there was no statistically significant differ-ence between the groups(P>0.05).Compared with before treatment,the expressions of GDF-15[(62.41±5.31)pg/L vs.(311.65±39.93)pg/L,(89.69±6.35)pg/L vs.(311.75±39.78)pg/L],hs-CRP[(12.60±1.17)mg/L vs.(29.37±2.46)mg/L,(16.77±1.15)mg/L vs.(29.18±2.28)mg/L],and CTNI[(0.05±0.01)μg/L vs.(2.51±0.53)μg/L,(0.12±0.01)μg/L vs.(2.64±0.58)μg/L]in both the combination group and dual antibody group were reduced after treatment(P<0.05),which were lower in the combination group(P<0.05).The incidence of major cardiovascular events during hospitalization in the combination group(12.22%)was lower than that in the dual antibody group(25.56%)(P<0.05).The difference in adverse reactions between the two groups(2.22%vs.1.11%)showed no statistical significance(P>0.05).Conclusion Shexiang Baoxin pill combined with dual antibody therapy has obvious advantages in the treatment of myocardial perfusion disturbance after PCI in patients with acute myocardial infarction,and can also promote the outcome of cardiac function and improve clinical prognosis.
Myocardial infarctionShexiangbaoxin pillsPercutaneous coronary interventionMyocardial perfusionCardiac function
万方数据
维普
